They gave sarizotan, a serotonergic 5-HT1A agonist, to patients with advanced PD with dyskinesias at 2 and 5 mg twice a day to 18 PD patients with dyskinesia. The gene discussed is HTR1A; the disease is drug-induced dyskinesia.